PUBLISHER: IMARC | PRODUCT CODE: 1541801
PUBLISHER: IMARC | PRODUCT CODE: 1541801
The global aptamers market size reached US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2032, exhibiting a growth rate (CAGR) of 17.8% during 2024-2032.
Aptamers are versatile oligonucleotides that bind to a specific target, including proteins, peptides, carbohydrates, small molecules, toxins, and live cells. They are modifiable, nonimmunogenic, highly sensitive, less toxic, easy to prepare and have low molecular weight and no variation with different preparations as compared to antibodies. As a result, they are widely being used in therapeutic and biotechnological applications. Besides this, they are also utilized as research agents, diagnostics, biosensors, and tools for biomarker or drug discovery worldwide.
The growing prevalence of life-threatening diseases, such as cancer, neurodegenerative, cardiovascular, and acquired immunodeficiency syndrome (AIDS), represents one of the key factors influencing the demand for new and effective detection assays based on aptamer therapy. Moreover, the advent of the chemical modification process to increase the nuclease resistance and enhance the therapeutic properties of aptamers is bolstering the market growth. The aptamers market growth can also be accredited to the rising number of research and development (R&D) activities undertaken for improving diagnostic devices and drugs and their carriers. Apart from this, as aptamers are chemically synthesized, which eliminates batch-to-batch variation and requires less time for development, their application is extensively increasing across the globe. Furthermore, private organizations are collaborating with academic institutes and research laboratories to introduce next-generation products and expand their existing market presence. This is anticipated to fuel the usage of aptamers in a wide range of medical therapies, as well as in the food and beverage (F&B) industry.
IMARC Group provides an analysis of the key trends in each sub-segment of the global aptamers market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type and application.
Nucleic Acid
Peptide
Diagnostics
Therapeutics
Research and Developments
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aptagen LLC, Aptamer Group, Aptamer Sciences Inc., Aptus Biotech S.L., Base Pair Biotechnologies Inc., IBA GmbH, Kaneka Eurogentec S.A. (Kaneka Corporation), NeoVentures Biotechnology Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies LLC and Vivonics Inc.